Research programme: ammonia oxidising bacteria-based therapeutics - AOBiome
Latest Information Update: 28 Sep 2022
Price :
$50 *
At a glance
- Originator AOBiome
- Class Antibacterials; Bacteria
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial vaginosis; Diabetic foot ulcer; Digestive system disorders; Eczema; Respiratory tract disorders; Rosacea
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Digestive system disorders in USA
- 28 Sep 2022 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA
- 28 Jul 2019 No recent reports of development identified for preclinical development in Bacterial-vaginosis in USA (Topical)